Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly to highlight key trial data at ASCO

Lilly to highlight key trial data at ASCO

17th May 2011

Lilly has announced that it will be presenting data from a number of key clinical trials at next month's American Society of Clinical Oncology (ASCO) annual meeting.

During the industry conference in Chicago, the company will showcase results from Paramount, a phase III trial of a new continuation maintenance regimen using Alimta for treating advanced nonsquamous non-small cell lung cancer.

It will compare the new therapy option to a placebo-based regime involving best supportive care.

The Paramount results will be offered alongside data from more than 30 other studies, including new analysis of drugs such as Gemzar and Erbitux, which will be presented with partners Bristol-Myers Squibb and Merck Serono.

Dr Richard Gaynor, vice-president for product development and medical affairs for Lilly Oncology, said: "We believe that data from Paramount and our other studies at ASCO demonstrate Lilly's focus on tailored therapies and commitment to addressing unmet needs in cancer care."

Last month, Lilly published its financial results for the first quarter of 2011, during which it experienced a year-on-year growth in revenue of six percent.ADNFCR-8000103-ID-800535891-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.